| AMGN |
Report |
Total revenue (Q2'26) |
BEAT |
pred ~$9.55B vs. cons $9.42B |
MEDIUM |
| AMGN |
Report |
Non-GAAP EPS (Q2'26) |
BEAT |
pred ~$5.72 vs. cons $5.59 |
MEDIUM |
| AMGN |
Report |
Repatha product sales (Q2'26) |
BEAT |
pred ~$925M vs. cons $904M |
LOW |
| AMGN |
Guide |
FY2026 revenue guidance |
UNCHANGED |
guide ~$37.1–38.5B (reaffirm, midpt ~$37.8B) vs. cons $38.0B (FY26) |
MEDIUM |
| AMGN |
Guide |
FY2026 non-GAAP EPS guidance |
UNCHANGED |
guide ~$21.70–23.10 (reaffirm, midpt ~$22.40) vs. cons $22.40 (FY26) |
MEDIUM |
| AMGN |
Guide |
FY2026 non-GAAP operating margin guidance |
UNCHANGED |
guide ~45–46% vs. cons ~45% (FY26) |
MEDIUM |
| AMGN |
Guide |
Cybersecurity incident quantified financial impact |
UNKNOWN |
guide ~$0 quantified/no material impact vs. cons ~$0 modeled (FY26 one-time) |
LOW |
| AMGN |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.0% |
— |
MEDIUM |
| AMGN |
Return |
5-day cumulative residual |
-3.0% (FOLLOW-THROUGH) |
Even on an in-line-to-modest beat with reaffirmed (not re-raised) guidance, the setup is a 'sell-the-news' after a ~+20% YTD run to a $393 late-July high and a full valuation; Q1'26 fell ~5% on a beat/raise, showing a high bar. Out-period math is negative: accelerating Prolia/XGEVA/Enbrel biosimilar erosion plus ~mid-single-digit Repatha price declines cap the sequential build, so 2027+ estimates get trimmed even as 2026 is defended. Add unquantified cyber-breach remediation/litigation risk and the imminent IRS Tax Court/2016–18 NOPA overhang. Low beta (~0.6) mutes the market offset, so idiosyncratic drift stays negative and follows through lower over the week. |
LOW |